<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p53" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_53{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_53{left:341px;bottom:30px;}
#t3_53{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_53{left:377px;bottom:30px;}
#t5_53{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_53{left:540px;bottom:30px;}
#t7_53{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_53{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_53{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_53{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_53{left:285px;bottom:827px;letter-spacing:-0.24px;}
#tc_53{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_53{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_53{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_53{left:1098px;bottom:28px;letter-spacing:0.32px;}
#tg_53{left:36px;bottom:215px;}
#th_53{left:46px;bottom:209px;letter-spacing:0.13px;}
#ti_53{left:247px;bottom:209px;}
#tj_53{left:36px;bottom:198px;}
#tk_53{left:46px;bottom:192px;letter-spacing:0.13px;}
#tl_53{left:261px;bottom:192px;}
#tm_53{left:36px;bottom:182px;}
#tn_53{left:42px;bottom:176px;letter-spacing:0.13px;word-spacing:-0.06px;}
#to_53{left:337px;bottom:176px;}
#tp_53{left:36px;bottom:165px;}
#tq_53{left:42px;bottom:159px;letter-spacing:0.12px;}
#tr_53{left:45px;bottom:142px;letter-spacing:0.11px;word-spacing:0.02px;}
#ts_53{left:45px;bottom:125px;letter-spacing:0.12px;}
#tt_53{left:268px;bottom:125px;letter-spacing:0.13px;}
#tu_53{left:352px;bottom:125px;}
#tv_53{left:36px;bottom:114px;}
#tw_53{left:46px;bottom:108px;letter-spacing:0.12px;word-spacing:-0.03px;}
#tx_53{left:556px;bottom:108px;}
#ty_53{left:36px;bottom:778px;letter-spacing:0.48px;}
#tz_53{left:36px;bottom:760px;letter-spacing:0.25px;}
#t10_53{left:188px;bottom:778px;letter-spacing:0.32px;word-spacing:-0.31px;}
#t11_53{left:732px;bottom:778px;letter-spacing:0.28px;word-spacing:-0.12px;}
#t12_53{left:1065px;bottom:511px;letter-spacing:-0.1px;}
#t13_53{left:1065px;bottom:493px;letter-spacing:-0.09px;}
#t14_53{left:1065px;bottom:475px;letter-spacing:-0.08px;}
#t15_53{left:1072px;bottom:415px;letter-spacing:-0.09px;}
#t16_53{left:1072px;bottom:396px;letter-spacing:-0.06px;}
#t17_53{left:1072px;bottom:378px;letter-spacing:-0.08px;}
#t18_53{left:1072px;bottom:360px;letter-spacing:-0.09px;}
#t19_53{left:1072px;bottom:341px;letter-spacing:-0.25px;}
#t1a_53{left:36px;bottom:549px;letter-spacing:-0.1px;}
#t1b_53{left:36px;bottom:530px;letter-spacing:-0.09px;}
#t1c_53{left:36px;bottom:512px;letter-spacing:-0.09px;}
#t1d_53{left:36px;bottom:494px;letter-spacing:-0.09px;}
#t1e_53{left:36px;bottom:475px;letter-spacing:-0.1px;}
#t1f_53{left:36px;bottom:457px;letter-spacing:-0.09px;}
#t1g_53{left:36px;bottom:439px;letter-spacing:-0.09px;}
#t1h_53{left:36px;bottom:420px;letter-spacing:-0.11px;}
#t1i_53{left:82px;bottom:428px;}
#t1j_53{left:90px;bottom:420px;}
#t1k_53{left:189px;bottom:731px;letter-spacing:-0.1px;word-spacing:-0.41px;}
#t1l_53{left:189px;bottom:713px;letter-spacing:-0.1px;}
#t1m_53{left:279px;bottom:720px;letter-spacing:-0.08px;}
#t1n_53{left:188px;bottom:243px;letter-spacing:-0.08px;}
#t1o_53{left:188px;bottom:280px;letter-spacing:-0.1px;}
#t1p_53{left:189px;bottom:685px;letter-spacing:-0.1px;}
#t1q_53{left:190px;bottom:659px;letter-spacing:-0.1px;}
#t1r_53{left:294px;bottom:667px;}
#t1s_53{left:190px;bottom:641px;letter-spacing:-0.09px;}
#t1t_53{left:190px;bottom:622px;letter-spacing:-0.09px;}
#t1u_53{left:190px;bottom:604px;letter-spacing:-0.09px;}
#t1v_53{left:190px;bottom:586px;letter-spacing:-0.09px;}
#t1w_53{left:190px;bottom:567px;letter-spacing:-0.1px;}
#t1x_53{left:189px;bottom:538px;letter-spacing:-0.1px;}
#t1y_53{left:188px;bottom:514px;letter-spacing:-0.1px;}
#t1z_53{left:188px;bottom:495px;letter-spacing:-0.08px;}
#t20_53{left:188px;bottom:477px;letter-spacing:-0.1px;}
#t21_53{left:188px;bottom:459px;letter-spacing:-0.09px;}
#t22_53{left:335px;bottom:466px;}
#t23_53{left:188px;bottom:393px;letter-spacing:-0.1px;}
#t24_53{left:188px;bottom:337px;letter-spacing:-0.09px;}
#t25_53{left:188px;bottom:319px;letter-spacing:-0.11px;}
#t26_53{left:303px;bottom:326px;letter-spacing:-0.14px;}
#t27_53{left:417px;bottom:584px;letter-spacing:-0.1px;}
#t28_53{left:417px;bottom:566px;letter-spacing:-0.09px;}
#t29_53{left:417px;bottom:548px;letter-spacing:-0.09px;}
#t2a_53{left:482px;bottom:555px;}
#t2b_53{left:732px;bottom:563px;letter-spacing:-0.11px;}
#t2c_53{left:833px;bottom:571px;}
#t2d_53{left:417px;bottom:461px;letter-spacing:-0.1px;}
#t2e_53{left:417px;bottom:443px;letter-spacing:-0.09px;}
#t2f_53{left:417px;bottom:425px;letter-spacing:-0.09px;}
#t2g_53{left:482px;bottom:432px;}
#t2h_53{left:539px;bottom:512px;letter-spacing:-0.09px;}
#t2i_53{left:539px;bottom:494px;letter-spacing:-0.09px;}
#t2j_53{left:539px;bottom:476px;letter-spacing:-0.26px;}
#t2k_53{left:661px;bottom:483px;}
#t2l_53{left:539px;bottom:410px;letter-spacing:-0.08px;}
#t2m_53{left:539px;bottom:391px;letter-spacing:-0.09px;}
#t2n_53{left:732px;bottom:501px;letter-spacing:-0.1px;}
#t2o_53{left:899px;bottom:508px;letter-spacing:-0.07px;}
#t2p_53{left:732px;bottom:482px;letter-spacing:-0.09px;}
#t2q_53{left:732px;bottom:419px;letter-spacing:-0.13px;}
#t2r_53{left:755px;bottom:427px;}
#t2s_53{left:732px;bottom:401px;letter-spacing:-0.06px;}
#t2t_53{left:732px;bottom:383px;letter-spacing:-0.1px;}
#t2u_53{left:975px;bottom:390px;letter-spacing:-0.09px;}
#t2v_53{left:729px;bottom:331px;letter-spacing:-0.1px;}
#t2w_53{left:729px;bottom:312px;letter-spacing:-0.1px;}
#t2x_53{left:833px;bottom:312px;letter-spacing:-0.11px;}
#t2y_53{left:649px;bottom:215px;}
#t2z_53{left:656px;bottom:209px;letter-spacing:0.09px;word-spacing:0.03px;}
#t30_53{left:658px;bottom:192px;letter-spacing:0.11px;}
#t31_53{left:748px;bottom:192px;letter-spacing:0.13px;word-spacing:-0.04px;}
#t32_53{left:658px;bottom:176px;letter-spacing:0.08px;word-spacing:0.06px;}
#t33_53{left:784px;bottom:176px;}
#t34_53{left:649px;bottom:165px;}
#t35_53{left:663px;bottom:159px;letter-spacing:0.12px;}
#t36_53{left:694px;bottom:159px;letter-spacing:0.12px;}
#t37_53{left:773px;bottom:159px;letter-spacing:0.08px;word-spacing:0.05px;}
#t38_53{left:649px;bottom:148px;}
#t39_53{left:660px;bottom:142px;letter-spacing:0.12px;}
#t3a_53{left:658px;bottom:125px;letter-spacing:0.12px;}
#t3b_53{left:658px;bottom:108px;letter-spacing:0.1px;word-spacing:0.02px;}
#t3c_53{left:443px;bottom:343px;letter-spacing:-0.09px;}
#t3d_53{left:443px;bottom:325px;letter-spacing:-0.09px;}
#t3e_53{left:443px;bottom:306px;letter-spacing:-0.09px;}
#t3f_53{left:443px;bottom:288px;letter-spacing:-0.11px;}
#t3g_53{left:516px;bottom:295px;}
#t3h_53{left:841px;bottom:673px;letter-spacing:-0.09px;}
#t3i_53{left:841px;bottom:655px;letter-spacing:-0.09px;}
#t3j_53{left:841px;bottom:636px;letter-spacing:-0.25px;}
#t3k_53{left:440px;bottom:664px;letter-spacing:-0.1px;}
#t3l_53{left:440px;bottom:644px;letter-spacing:-0.09px;}
#t3m_53{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_53{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_53{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_53{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_53{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_53{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_53{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_53{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_53{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_53{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_53{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sa_53{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_53{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sc_53{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts53" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg53Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg53" style="-webkit-user-select: none;"><object width="1210" height="935" data="53/53.svg" type="image/svg+xml" id="pdf53" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_53" class="t s0_53">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_53" class="t s1_53">® </span>
<span id="t3_53" class="t s0_53">(NCCN </span>
<span id="t4_53" class="t s1_53">® </span>
<span id="t5_53" class="t s0_53">), All rights reserved. NCCN Guidelines </span>
<span id="t6_53" class="t s1_53">® </span>
<span id="t7_53" class="t s0_53">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_53" class="t s2_53">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_53" class="t s2_53">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_53" class="t s3_53">NCCN Guidelines Version 4.2024 </span>
<span id="tb_53" class="t s3_53">Cancer of the Supraglottic Larynx </span>
<span id="tc_53" class="t s4_53">NCCN Guidelines Index </span>
<span id="td_53" class="t s4_53">Table of Contents </span>
<span id="te_53" class="t s4_53">Discussion </span>
<span id="tf_53" class="t s5_53">SUPRA-5 </span>
<span id="tg_53" class="t s6_53">d </span>
<span id="th_53" class="t s7_53">Principles of Imaging (IMG-A)</span><span id="ti_53" class="t s8_53">. </span>
<span id="tj_53" class="t s6_53">h </span>
<span id="tk_53" class="t s7_53">Principles of Surgery (SURG-A)</span><span id="tl_53" class="t s8_53">. </span>
<span id="tm_53" class="t s6_53">i </span>
<span id="tn_53" class="t s7_53">Principles of Radiation Therapy (SUPRA-A)</span><span id="to_53" class="t s8_53">. </span>
<span id="tp_53" class="t s6_53">j </span>
<span id="tq_53" class="t s8_53">Adverse pathologic features: extranodal extension, positive margins, close margins, </span>
<span id="tr_53" class="t s8_53">pT3 or pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular </span>
<span id="ts_53" class="t s8_53">invasion, and lymphatic invasion </span><span id="tt_53" class="t s7_53">(Discussion)</span><span id="tu_53" class="t s8_53">. </span>
<span id="tv_53" class="t s6_53">k </span>
<span id="tw_53" class="t s7_53">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="tx_53" class="t s8_53">. </span>
<span id="ty_53" class="t s5_53">CLINICAL </span>
<span id="tz_53" class="t s5_53">STAGING </span>
<span id="t10_53" class="t s5_53">TREATMENT OF PRIMARY AND NECK </span><span id="t11_53" class="t s5_53">ADJUVANT TREATMENT </span>
<span id="t12_53" class="t s5_53">Follow-up </span>
<span id="t13_53" class="t s9_53">(FOLL-A, 1 </span>
<span id="t14_53" class="t s9_53">of 2) </span>
<span id="t15_53" class="t s5_53">Recurrent </span>
<span id="t16_53" class="t s5_53">or </span>
<span id="t17_53" class="t s5_53">persistent </span>
<span id="t18_53" class="t s5_53">disease </span>
<span id="t19_53" class="t s9_53">(ADV-3) </span>
<span id="t1a_53" class="t s5_53">Amenable to </span>
<span id="t1b_53" class="t s5_53">larynx- </span>
<span id="t1c_53" class="t s5_53">preserving </span>
<span id="t1d_53" class="t s5_53">(conservation) </span>
<span id="t1e_53" class="t s5_53">surgery </span>
<span id="t1f_53" class="t s5_53">(T1–2,N+ and </span>
<span id="t1g_53" class="t s5_53">selected </span>
<span id="t1h_53" class="t s5_53">T3,N1 </span>
<span id="t1i_53" class="t sa_53">h </span>
<span id="t1j_53" class="t s5_53">) </span>
<span id="t1k_53" class="t s5_53">Concurrent systemic </span>
<span id="t1l_53" class="t s5_53">therapy/RT </span>
<span id="t1m_53" class="t sa_53">i,k,l </span>
<span id="t1n_53" class="t s5_53">Clinical trials </span>
<span id="t1o_53" class="t s5_53">or </span>
<span id="t1p_53" class="t s5_53">or </span>
<span id="t1q_53" class="t sb_53" data-mappings='[[2,"fi"]]'>Deﬁnitive RT </span>
<span id="t1r_53" class="t sa_53">i </span>
<span id="t1s_53" class="t s5_53">for low-volume </span>
<span id="t1t_53" class="t s5_53">disease (T1–2,N1) or </span>
<span id="t1u_53" class="t s5_53">patients medically </span>
<span id="t1v_53" class="t sb_53" data-mappings='[[2,"fi"]]'>unﬁt for systemic </span>
<span id="t1w_53" class="t s5_53">therapy </span>
<span id="t1x_53" class="t s5_53">or </span>
<span id="t1y_53" class="t s5_53">Endoscopic or </span>
<span id="t1z_53" class="t s5_53">open partial </span>
<span id="t20_53" class="t s5_53">laryngectomy and </span>
<span id="t21_53" class="t s5_53">neck dissection(s) </span>
<span id="t22_53" class="t sa_53">h </span>
<span id="t23_53" class="t s5_53">or </span>
<span id="t24_53" class="t s5_53">Induction </span>
<span id="t25_53" class="t s5_53">chemotherapy </span>
<span id="t26_53" class="t sa_53">k,m </span>
<span id="t27_53" class="t s5_53">No adverse </span>
<span id="t28_53" class="t s5_53">pathologic </span>
<span id="t29_53" class="t s5_53">features </span>
<span id="t2a_53" class="t sa_53">j </span>
<span id="t2b_53" class="t s5_53">Consider RT </span>
<span id="t2c_53" class="t sa_53">i </span>
<span id="t2d_53" class="t s5_53">Adverse </span>
<span id="t2e_53" class="t s5_53">pathologic </span>
<span id="t2f_53" class="t s5_53">features </span>
<span id="t2g_53" class="t sa_53">j </span>
<span id="t2h_53" class="t s5_53">Extranodal </span>
<span id="t2i_53" class="t s5_53">extension and/or </span>
<span id="t2j_53" class="t s5_53">positive margin </span>
<span id="t2k_53" class="t sa_53">n </span>
<span id="t2l_53" class="t s5_53">Other risk </span>
<span id="t2m_53" class="t s5_53">features </span>
<span id="t2n_53" class="t s5_53">Systemic therapy/RT </span>
<span id="t2o_53" class="t sa_53">i,k </span>
<span id="t2p_53" class="t s5_53">(category 1) </span>
<span id="t2q_53" class="t s5_53">RT </span>
<span id="t2r_53" class="t sa_53">i </span>
<span id="t2s_53" class="t s5_53">or </span>
<span id="t2t_53" class="t s5_53">Consider systemic therapy/RT </span>
<span id="t2u_53" class="t sa_53">i,k </span>
<span id="t2v_53" class="t s5_53">Response </span>
<span id="t2w_53" class="t s5_53">Assessment </span><span id="t2x_53" class="t s9_53">(SUPRA-7) </span>
<span id="t2y_53" class="t s6_53">l </span>
<span id="t2z_53" class="t s8_53">When using concurrent systemic therapy/RT, the preferred agent is cisplatin </span>
<span id="t30_53" class="t s8_53">(category 1). </span><span id="t31_53" class="t s7_53">See Principles of Systemic Therapy for Non-Nasopharyngeal </span>
<span id="t32_53" class="t s7_53">Cancers (SYST-A)</span><span id="t33_53" class="t s8_53">. </span>
<span id="t34_53" class="t s6_53">m </span>
<span id="t35_53" class="t s8_53">See </span><span id="t36_53" class="t s7_53">Discussion </span><span id="t37_53" class="t s8_53">on induction chemotherapy. </span>
<span id="t38_53" class="t s6_53">n </span>
<span id="t39_53" class="t s8_53">In highly select patients, re-resection (if negative margins are feasible and </span>
<span id="t3a_53" class="t s8_53">can be achieved without total laryngectomy) where it would potentially </span>
<span id="t3b_53" class="t s8_53">change the subsequent indication for chemotherapy. </span>
<span id="t3c_53" class="t s5_53">CT (with contrast) or </span>
<span id="t3d_53" class="t s5_53">MRI (with and without </span>
<span id="t3e_53" class="t s5_53">contrast) of primary </span>
<span id="t3f_53" class="t s5_53">and neck </span>
<span id="t3g_53" class="t sa_53">d </span>
<span id="t3h_53" class="t s5_53">Recurrent or </span>
<span id="t3i_53" class="t s5_53">persistent disease </span>
<span id="t3j_53" class="t s9_53">(ADV-3) </span>
<span id="t3k_53" class="t s9_53">Post Systemic Therapy/RT or RT </span>
<span id="t3l_53" class="t s9_53">Neck Evaluation (FOLL-A, 2 of 2) </span>
<span id="t3m_53" class="t sc_53">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
